top of page

Benralizumab phase III trials show positive results in severe asthma

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.


Click on this link for more information.

source: http://www.worldpharmanews.com/astrazeneca/3611-benralizumab-phase-iii-trials-show-positive-results-in-severe-asthma

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page